Meta-analysis of efficacy and safety of adalimumab injection for arthropathic psoriasis

Abstract

Objective: To systematically evaluate the efficacy and safety of adalimumab injection for arthropathic psoriasis. Methods: Randomized controlled trials (RCTs) of adalimumab versus methotrexate for arthropathic psoriasis published in both English and Chinese were searched on the websites of CNKI, Wanfang Database, China Biomedical Literature Database, Pubmed, Medline and Embase (January 2000 to October 2018). The quality of these studies was evaluated according to the method of Cochrane systematic evaluation. Meta-analysis was performed using RevMan 5.1 software. Results: A total of 5 RCTs, including 555 patients with arthropathic psoriasis, were included in this analysis. Following 3-month treatments, adalimumab injection significantly decreased PASI scores [SMD=1.86, 95% CI (1.29, 2.68), P<0.01], joint tenderness scores [SMD=4.95, 95% CI (2.74, 7.15), P<0.01] and joint swelling scores [SMD=2.73, 95% CI (1.65, 3.80), P<0.01] in comparison to methotrexate treatment. The effective rate was also higher in adalimumab than in methotrexate treatment [OR=2.90, 95% CI (2.01, 4.19), P<0.01]. In addition, the rate of adverse reactions was lower in adalimumab than in methotrexate treatment [OR=0.47, 95% CI (0.20, 1.09), P=0.08]. Conclusion: Adalimumab injection is effective and safe for arthropathic psoriasis.

Keywords

• adalimumab
• arthropathic psoriasis
• randomized controlled trials
• systematic evaluation